MedTrace Logo

Pharmacoepidemiological Study of Secondary Hyperparathyroidism in Lorraine

NCT02888639 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 305

Last updated 2016-09-05

No results posted yet for this study

Summary

The pharmacoepidemiological EPHEYL (Étude PHarmacoÉpidémiologique de l'hYperparathyroïdie secondaire en Lorraine) study is a 2-year, open-cohort, prospective, observational study on incident SHPT, i.e. newly diagnosed, with a 2 year follow-up, set in the 12 dialysis units located in the French region of Lorraine (public or private).

Conditions

  • ESRD

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Luc Frimat, MD, PhD · CHRU de Nancy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-05-31
Completion
2012-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02888639 on ClinicalTrials.gov